Aastrom Biosciences (US) gets investigational device exemption (IDE) for stem cell production trial:
This article was originally published in Clinica
Aastrom Biosciences (US) says it has FDA permission to begin clinical trials of its cell production system (CPS) for cancer patients. The first phase of the trials will involve the treatment of ten breast cancer patients at the MD Anderson Cancer Center, Houston, Tx. Aastrom says that CPS, which produces human stem cells from a 15 ml bone marrow sample, is a much less cumbersome method than those currently used to produce stem cells outside the body.
You may also be interested in...
The series D financing will support the expansion of Everlywell’s consumer lab testing and digital health businesses.
New guidance from the UK regulator covers distribution and deployment of Pfizer/BioNTech's COVID-19 vaccine, which will be complex because of the temperature storage requirements and the large packs in which the vaccine doses will be delivered.
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.